[Table/Fig-4]:
The description of studies that met our eligibility criteria*Number of participants**Prevalence*** Confidence Interval
| Researcher | Year | n* | locations | p** (%) | CI 95%*** |
|---|---|---|---|---|---|
| Jabeen | 1996 | 200 | Pakistan | 41 | 34-48 |
| Silva | 2003 | 1395 | Brazil | 60 | 58-63 |
| Potter | 2003 | 2863 | France | 12 | 10.8-13.2 |
| Antai | 2004 | 200 | Nigeria | 85 | 80.1- 89.9 |
| Tabassum | 2004 | 384 | Pakistan | 53 | 47.8-58.2 |
| Bakhshani | 2005 | 300 | Iran | 98.2 | 96.7-99.7 |
| Sibel | 2006 | 1992 | Turkey | 79 | 74.9-83.1 |
| Nisar | 2006 | 172 | Pakistan | 51 | 43.5-58.5 |
| Rizk | 2006 | 700 | United Arab Emirates | 16.8 | 14-19.6 |
| Knauss | 2007 | 3518 | Switzerland | 19 | 17.7-20.3 |
| Erbil | 2007 | 300 | Turkey | 49.7 | 44-55.4 |
| Tschudin | 2007 | 3913 | Switzerland | 10 | 9.1-10.9 |
| Lete | 2008 | 2018 | Spain | 73 | 70.8-75.2 |
| Butsripoom | 2009 | 161 | Thailand | 16.8 | 10.9-29.7 |
| Carlos | 2009 | 1053 | Brazil | 60 | 57-63 |
| Lakshmi | 2011 | 300 | India | 67 | 61.7-72.3 |
| Qiao | 2011 | 947 | China | 21 | 19.8-22.2 |
| Total | 18803 | 47.8 | 32.6-69.9 |